Table 1 Patient and tumor characteristics at baseline

Number of the patients

46

45

Age; median (range)

63 (51–87)

62 (49–87)

Follow-up period (weeks); median (range)

69 (13–144)

81 (13–160)

Time elapsed after menopause (years); median (range)

13 (2–37)

13 (1–37)

Body Mass Index; median (range)

22.9 (18.0-35.2)

23.4 (27.7-35.4)

DFI in recurrent cases (months); median (range)

70 (5–188)

60 (1–189)

Estrogen Receptor status

Positive

45

42

Negative

0

1

Unknown

1

2

Progesterone Receptor status

Positive

27

31

Negative

17

11

Unknown

2

3

HER2 status

Negative

43

40

Positive

1

1

Unknown

2

4

Main metastatic lesion

  Visceral disease (main organ)

Lung

10

10

Liver

7

6

Pleura

5

3

  Non-visceral disease

Bone

9 (20%)

14 (31%)

Soft tissue

15

12

Performance status (cases)

0,1

45

44

2

1

1

No. of previous therapies (%)

1

28

29

2

41

42

3

24

18

≥4

9

11

Previous aromatase inhibitor (%)

Anastrozole

48

47

Letrozole

52

53

Previous treatment with tamoxifen (%)

21

24

Previous chemotherapy (%)

44

38

Sensitivity to previous aromatase inhibitor treatment;

  Clinical Benefit Rate (%)

17/23 (74%)

20/30 (67%)

  Duration of previous aromatase inhibitor(months); median (range)

17.1 (2.0-80.8)

17.6 (2.4-65.3)